Octreotide

Mechanism

A synthetic version of somatostatin — the body's "off switch" for hormone release. It suppresses growth hormone, insulin, glucagon, and gut hormones. FDA-approved for acromegaly (excess GH), carcinoid tumors, and severe diarrhea. Important in the peptide space because it's the opposite of GH-releasing peptides.

Effects

**Endocrine — Somatostatin System (Tier 1 — Human Clinical):** Octreotide is the prototypical synthetic somatostatin analog, binding preferentially to SSTR2 and SSTR5. It suppresses GH, IGF-1, insulin, glucagon, VIP, serotonin, gastrin, secretin, motilin, and other GI/pancreatic hormones. Half-life of 1.5 hours (SC) vs 1.5 minutes for native somatostatin, with LAR formulation providing 28-day coverage. **Gastrointestinal (Tier 1 — Human Clinical):** Reduces GI secretions, slows motility, decreases splanchnic blood flow. Cornerstone of carcinoid syndrome management — controls diarrhea (60–80% improvement) and flushing (50–70% improvement). Also used for variceal bleeding (reduces portal pressure), VIPomas, and refractory diarrhea from various causes. **Tumor Growth Inhibition (Tier 1 — Human Clinical):** PROMID trial demonstrated octreotide LAR significantly prolongs time to tumor progression in metastatic midgut NETs (14.3 months vs 6 months placebo). Anti-proliferative effect through SSTR2-mediated cell cycle arrest. **Hepatobiliary (Tier 1 — Side Effect):** Gallstone formation in 15–30% of patients on chronic therapy due to reduced gallbladder motility and altered bile composition. Most are cholesterol stones. **Metabolic (Tier 1 — Human Clinical):** Suppresses insulin secretion, causing hyperglycemia in some patients. Also suppresses glucagon, which may partially offset the glucose effect. Net metabolic impact is variable — some patients experience improved glucose control (in insulinoma), while others worsen (in acromegaly/NETs). **Pancreatic Exocrine (Tier 1 — Human Clinical):** Reduces pancreatic enzyme secretion. Used to manage pancreatic fistulas and reduce output in patients with external pancreatic drainage. Also used post-pancreatic surgery to reduce leak rates.

Practitioner Guide

**APPROVED INDICATIONS:** • Acromegaly. • Carcinoid syndrome (severe diarrhea and flushing). • VIPomas (watery diarrhea). • Available as Sandostatin (immediate-release SC) and Sandostatin LAR (long-acting IM depot). **DOSING:** • Immediate-release: 50–200 mcg SC two to three times daily. Start low and titrate. • LAR depot: 20 mg IM (gluteal) every 28 days. May increase to 30 mg or 40 mg based on response. • Bridge therapy: When starting LAR, continue SC octreotide for 2 weeks (time needed for depot drug release to reach steady state). • Carcinoid crisis prevention: Pre-operative IV octreotide 250–500 mcg bolus, followed by infusion, in patients with carcinoid tumors undergoing surgery or hepatic artery embolization. **GALLSTONE PREVENTION (Deep Clinical Pearls):** • Same strategies as lanreotide: prophylactic UDCA 300 mg BID, adequate dietary fat intake, baseline and annual gallbladder ultrasounds. • Clinical pearl: Patients on octreotide who develop RUQ pain should be evaluated for biliary pathology even if recent ultrasound was normal — sludge can progress to symptomatic stones quickly. • Cholecystectomy is NOT routinely recommended prophylactically. Only for symptomatic cholelithiasis or complications (cholecystitis, choledocholithiasis). **MANAGING HYPERGLYCEMIA:** • Monitor glucose carefully during initiation and dose changes. The insulin-suppressive effect typically predominates, causing hyperglycemia, but occasional patients experience hypoglycemia if glucagon suppression is greater. • Start or adjust diabetes medications proactively. Metformin first-line; insulin may be needed. • Clinical pearl: Hyperglycemia is more predictable and manageable with octreotide and lanreotide than with pasireotide, which causes severe hyperglycemia in a high percentage of patients. **LAR INJECTION TECHNIQUE (Deep Clinical Pearls):** • The LAR preparation is a microsphere suspension that MUST be injected intramuscularly in the gluteal region — NOT subcutaneous. • Reconstitution: Add diluent to microsphere vial, swirl (do NOT shake vigorously — shaking damages microspheres). Let foam settle. Draw up immediately and inject promptly — the suspension settles quickly. • Use the provided 20G needle — the microspheres will clog smaller needles. Inject into the gluteal muscle (upper outer quadrant), alternating sides monthly. • Inject with steady pressure. Do NOT massage the injection site afterward. • Room temperature preparation: Remove LAR kit from refrigerator 30–60 minutes before injection. Cold preparation is more painful and may affect microsphere dispersal. • Clinical pearl: LAR injections should be performed by trained healthcare providers. The injection technique significantly affects drug release kinetics — too superficial (subcutaneous) means erratic absorption and reduced efficacy. **INTERACTION WITH GH PEPTIDE COMMUNITY (Deep Guidance):** • In the GH peptide / performance community, octreotide (immediate-release) is sometimes used to suppress unwanted GH side effects: excessive water retention, joint pain, carpal tunnel-like symptoms, or to "control" GH spikes from secretagogue use. • Typical off-label pattern: 50–100 mcg SC of octreotide taken when GH side effects become bothersome, or as a "GH brake" at night to limit extended GH exposure. • Why this is problematic: (1) Octreotide suppresses not just GH but also insulin, glucagon, and gut hormones. Random use disrupts multiple hormonal systems. (2) Gallstone risk begins accumulating even with intermittent use. (3) GI side effects (diarrhea, cramping, nausea) are common and unpleasant. (4) If GH peptide doses are causing symptoms requiring octreotide to manage, the correct answer is to REDUCE the GH peptide dose, not add another pharmaceutical. • Clinical pearl: The rare legitimate scenario for concurrent use is a patient with acromegaly or a pituitary tumor who is also being evaluated for GH secretagogue sensitivity. In all other cases, "using octreotide to control GH peptide side effects" is a red flag for excessive GH peptide dosing.

Dosing Protocols

Contraindications & Cautions

• hard stop — Pregnancy
  Limited human data. Animal studies showed potential for decreased fetal weight. Hormonal suppression during pregnancy could affect fetal development.
  Action: Do not use during pregnancy unless clearly necessary under specialist care.
• hard stop — Under 18 years of age
  Somatostatin analog. Pediatric use only under specialist supervision.
  Action: Do not provide outside specialist care.
• caution — Gallbladder disease or history of gallstones
  Octreotide (Sandostatin) promotes gallstone formation in up to 25% of patients on long-term therapy. It reduces gallbladder motility and alters bile composition, promoting cholesterol stone formation.
  Action: Monitor for gallbladder symptoms. Ultrasound recommended at baseline and periodically. Consider ursodeoxycholic acid prophylaxis for long-term use.
• requires physician — Diabetes
  Octreotide suppresses both insulin and glucagon secretion. The net effect on blood glucose is variable and unpredictable — it may worsen hyperglycemia in some patients and cause hypoglycemia in others. Glycemic management becomes significantly more complex.
  Action: Requires physician supervision. Frequent blood glucose monitoring mandatory. Diabetes medication adjustment likely needed. Monitor HbA1c.
• monitor — Hypothyroidism
  Octreotide suppresses TSH secretion and may worsen or unmask hypothyroidism. Thyroid function may decline during treatment.
  Action: Monitor thyroid function tests (TSH, free T4) at baseline and periodically. Thyroid hormone replacement dose may need adjustment.
• caution — QT prolongation or QT-prolonging medications
  Octreotide may prolong the QT interval, particularly via bradycardia. Concurrent use with other QT-prolonging drugs increases the risk of torsades de pointes.
  Action: ECG monitoring recommended. Monitor electrolytes. Avoid concurrent QT-prolonging medications when possible.

Evidence

• Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1.

  Ferone et al. (2025) — J Clin Endocrinol Metab — PMID: 39378125

  Phase 3 ACROINNOVA 1 data support subcutaneous depot octreotide for maintaining biochemical control in acromegaly, expanding contemporary evidence for depot delivery beyond older LAR studies.

  strong

• Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome

  Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, Saltz L, Dandona P, Anthony L (1999) — Journal of Clinical Oncology — PMID: 10561197

  Octreotide LAR (long-acting release) monthly intramuscular injection was as effective as thrice-daily subcutaneous octreotide for controlling symptoms of malignant carcinoid syndrome (flushing, diarrhea). Biochemical response (5-HIAA reduction) was comparable between formulations. Monthly dosing dramatically improved patient convenience and compliance. FDA-approved for acromegaly, carcinoid syndrome, and VIPomas.

  strong

• SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action

  Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless J (1982) — Life Sciences — PMID: 6128648

  Octreotide (SMS 201-995) was characterized as a synthetic octapeptide somatostatin analog with 45x greater potency than native somatostatin for GH suppression and dramatically longer half-life (90 minutes vs 1-3 minutes). Selective inhibition of GH over insulin secretion was a key therapeutic advantage. This paper launched the somatostatin analog class that would become standard of care for acromegaly and neuroendocrine tumors.

  strong

Research Summary

**Tier 1 (Human Clinical Evidence):** • PROMID trial (JCO, 2009): Octreotide LAR 30 mg monthly significantly prolonged time to tumor progression vs placebo in midgut NETs. Landmark trial establishing somatostatin analogs as anti-proliferative therapy, not just symptom control. • Acromegaly: Decades of clinical data. Normalizes GH/IGF-1 in 50–65% of patients. First-line medical therapy for acromegaly worldwide. • Carcinoid syndrome: Standard of care for symptom management. 60–80% improvement in diarrhea, 50–70% reduction in flushing. • Variceal bleeding: RCTs support octreotide (IV) as adjunct to endoscopic therapy for acute variceal hemorrhage. • Safety: Well-characterized side effect profile. Gallstones, GI disturbance, and injection site reactions are main issues. **Tier 2 (Strong Preclinical + Mechanistic):** • SSTR2/SSTR5 pharmacology extensively characterized. Crystal structure of octreotide-SSTR2 complex has been solved. • Anti-proliferative mechanism: SSTR2 activation leads to phosphotyrosine phosphatase recruitment, cell cycle arrest, and apoptosis induction in tumor cells. **Tier 3 (Emerging / Theoretical):** • Peptide receptor radionuclide therapy (PRRT): 177Lu-DOTATATE (Lutathera) is a radiolabeled somatostatin analog for NET treatment. Built on octreotide receptor targeting platform. • Combination with newer targeted therapies for NETs is under investigation.